Connection | Profiles RNS

Search Result Details

Back to Search Results

This page shows the details of why an item matched the keywords from your search.

Search Results

VERSTOVSEK, SRDAN

One or more keywords matched the following items that are connected to VERSTOVSEK, SRDAN

Item Type	Name
Academic Article	Polycythemia vera is not initiated by JAK2V617F mutation.
Academic Article	The JAK kinase inhibitor CP-690,550 suppresses the growth of human polycythemia vera cells carrying the JAK2V617F mutation.
Academic Article	Bone marrow stroma-secreted cytokines protect JAK2(V617F)-mutated cells from the effects of a JAK2 inhibitor.
Academic Article	Imatinib effect on growth and signal transduction in polycythemia vera.
Academic Article	Preclinical characterization of atiprimod, a novel JAK2 AND JAK3 inhibitor.
Concept	Janus Kinase 1
Concept	Janus Kinase 3
Concept	Janus Kinase 2
Academic Article	Heat shock protein 90 inhibitor is synergistic with JAK2 inhibitor and overcomes resistance to JAK2-TKI in human myeloproliferative neoplasm cells.
Academic Article	Dual PI3K/AKT/mTOR inhibitor BEZ235 synergistically enhances the activity of JAK2 inhibitor against cultured and primary human myeloproliferative neoplasm cells.
Academic Article	JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia.
Academic Article	Experience with oral interferon-alpha in patients with essential thrombocythemia and polycythemia vera.
Academic Article	WP1066, a novel JAK2 inhibitor, suppresses proliferation and induces apoptosis in erythroid human cells carrying the JAK2 V617F mutation.
Academic Article	BCR-ABL1-positive CML and BCR-ABL1-negative chronic myeloproliferative disorders: some common and contrasting features.
Academic Article	Mutation profile of JAK2 transcripts in patients with chronic myeloproliferative neoplasias.
Academic Article	Experimental therapeutics for patients with myeloproliferative neoplasias.
Academic Article	Competing cell clones in myeloproliferative neoplasm.
Academic Article	JAK2 inhibitors: are they the solution?
Academic Article	Breakthroughs in myeloproliferative neoplasms.
Academic Article	Heterodimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapy.
Academic Article	What is next beyond janus kinase 2 inhibitors for primary myelofibrosis?
Academic Article	Phase I evaluation of XL019, an oral, potent, and selective JAK2 inhibitor.
Academic Article	Myelodysplastic/myeloproliferative neoplasms, unclassifiable (MDS/MPN, U): natural history and clinical outcome by treatment strategy.
Academic Article	Efficacy of ruxolitinib for myelofibrosis.
Academic Article	International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT).
Academic Article	Treatment of myelofibrosis in younger patients: to transplant or not?
Academic Article	JAK2 inhibitors and myeloproliferative neoplasms.
Academic Article	JAK2 inhibitors: A reality? A hope?
Academic Article	Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias.
Academic Article	Aberrant myeloid maturation identified by flow cytometry in primary myelofibrosis.
Academic Article	Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms.
Academic Article	Therapeutic potential of Janus-activated kinase-2 inhibitors for the management of myelofibrosis.
Academic Article	Janus-activated kinase 2 inhibitors: a new era of targeted therapies providing significant clinical benefit for Philadelphia chromosome-negative myeloproliferative neoplasms.
Academic Article	Evaluating the serial use of the Myelofibrosis Symptom Assessment Form for measuring symptomatic improvement: performance in 87 myelofibrosis patients on a JAK1 and JAK2 inhibitor (INCB018424) clinical trial.
Academic Article	Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemia.
Academic Article	Janus kinase inhibition and its effect upon the therapeutic landscape for myelofibrosis: from palliation to cure?
Academic Article	JAK2 inhibitors for myelofibrosis: why are they effective in patients with and without JAK2V617F mutation?
Academic Article	Splenomegaly in myelofibrosis--new options for therapy and the therapeutic potential of Janus kinase 2 inhibitors.
Academic Article	Therapeutic effects of ruxolitinib in patients with myelofibrosis without clinically significant splenomegaly.
Academic Article	Emerging drugs for myelofibrosis.
Academic Article	Ruxolitinib: an oral Janus kinase 1 and Janus kinase 2 inhibitor in the management of myelofibrosis.
Academic Article	Investigational Janus kinase inhibitors.
Academic Article	Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon a-2a.
Academic Article	Bone marrow fibrosis in patients with primary myelodysplastic syndromes has prognostic value using current therapies and new risk stratification systems.
Academic Article	Hemizygous/homozygous and heterozygous JAK2 mutation detected in plasma of patients with myeloproliferative diseases: correlation with clinical behaviour.
Academic Article	High occurrence of JAK2 V617 mutation in refractory anemia with ringed sideroblasts associated with marked thrombocytosis.
Academic Article	JAK2V617F mutational frequency in polycythemia vera: 100%, >90%, less?
Academic Article	Experimental therapy in myelofibrosis with myeloid metaplasia.
Academic Article	Prognostic interaction between thrombocytosis and JAK2 V617F mutation in the WHO subcategories of myelodysplastic/myeloproliferative disease-unclassifiable and refractory anemia with ringed sideroblasts and marked thrombocytosis.
Academic Article	TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patients.
Academic Article	Plasma levels of JAK2 mRNA in patients with chronic myeloproliferative diseases with and without V617F mutation: implications for prognosis and disease biology.
Academic Article	Prospect of JAK2 inhibitor therapy in myeloproliferative neoplasms.
Academic Article	Imatinib mesylate therapy for polycythemia vera: final result of a phase II study initiated in 2001.
Academic Article	Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis.
Academic Article	Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera.
Academic Article	Distinct patterns of cytogenetic and clinical progression in chronic myeloproliferative neoplasms with or without JAK2 or MPL mutations.
Academic Article	Conventional and experimental drug therapy in myelofibrosis with myeloid metaplasia.
Academic Article	Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis.
Academic Article	JAK2 inhibitors: what's the true therapeutic potential?
Academic Article	Spleen deflation and beyond: the pros and cons of Janus kinase 2 inhibitor therapy for patients with myeloproliferative neoplasms.
Academic Article	Ruxolitinib for the treatment of myelofibrosis.
Academic Article	A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis.
Academic Article	Advances in the management of myelofibrosis.
Academic Article	Molecular pathways: Jak/STAT pathway: mutations, inhibitors, and resistance.
Academic Article	Validation of standards for quantitative assessment of JAK2 c.1849G>T (p.V617F) allele burden analysis in clinical samples.
Academic Article	The clinical importance of moderate/severe bone marrow fibrosis in patients with therapy-related myelodysplastic syndromes.
Academic Article	A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 Inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea.
Academic Article	Stimulation of the B-cell receptor activates the JAK2/STAT3 signaling pathway in chronic lymphocytic leukemia cells.
Academic Article	A phase II study of 5-azacitidine for patients with primary and post-essential thrombocythemia/polycythemia vera myelofibrosis.
Academic Article	The natural history and treatment outcome of blast phase BCR-ABL- myeloproliferative neoplasms.
Academic Article	Therapeutic potential of JAK2 inhibitors.
Academic Article	Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond.
Academic Article	Ruxolitinib: a new JAK1/2 inhibitor that offers promising options for treatment of myelofibrosis.
Academic Article	Therapy with JAK2 inhibitors for myeloproliferative neoplasms.
Academic Article	Lenalidomide therapy in myelofibrosis with myeloid metaplasia.
Academic Article	Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis.
Academic Article	New JAK2 inhibitors for myeloproliferative neoplasms.
Academic Article	Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls.
Academic Article	JAK2 p.V617F detection and allele burden measurement in peripheral blood and bone marrow aspirates in patients with myeloproliferative neoplasms.
Academic Article	Discrepancy in diagnosis of primary myelofibrosis between referral and tertiary care centers.
Academic Article	Therapeutic options for patients with polycythemia vera and essential thrombocythemia refractory/resistant to hydroxyurea.
Academic Article	Janus kinase inhibitors and allogeneic stem cell transplantation for myelofibrosis.
Academic Article	A phase I/II study of the Janus kinase (JAK)1 and 2 inhibitor ruxolitinib in patients with relapsed or refractory acute myeloid leukemia.
Academic Article	Genomic and functional analysis of leukemic transformation of myeloproliferative neoplasms.
Academic Article	A phase I, open-label, multi-center study of the JAK2 inhibitor AZD1480 in patients with myelofibrosis.
Academic Article	Historical views, conventional approaches, and evolving management strategies for myeloproliferative neoplasms.
Academic Article	JAK2V617F complete molecular remission in polycythemia vera/essential thrombocythemia patients treated with ruxolitinib.
Academic Article	A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis.
Academic Article	Chronic myelogenous leukemia in patients with MPL or JAK2 mutation-positive myeloproliferative neoplasm.
Academic Article	Ruxolitinib in combination with lenalidomide as therapy for patients with myelofibrosis.
Academic Article	Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib.
Academic Article	The effect of long-term ruxolitinib treatment on JAK2p.V617F allele burden in patients with myelofibrosis.
Academic Article	A comprehensive review of pacritinib in myelofibrosis.
Academic Article	Clinical validation of a multipurpose assay for detection and genotyping of CALR mutations in myeloproliferative neoplasms.
Academic Article	Outcomes of Allogeneic Hematopoietic Cell Transplantation in?Patients with Myelofibrosis with Prior Exposure to Janus Kinase 1/2 Inhibitors.
Academic Article	BET protein bromodomain inhibitor-based combinations are highly active against post-myeloproliferative neoplasm secondary AML cells.
Academic Article	Comprehensive kinase profile of pacritinib, a nonmyelosuppressive janus kinase 2 inhibitor
Academic Article	Chronic lymphocytic leukemia and myeloproliferative neoplasms concurrently diagnosed: clinical and biological characteristics.
Academic Article	DNMT3A, TET2, and JAK2 mutations in polycythemia vera following long-term remission of secondary acute myeloid leukemia.
Academic Article	Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib.
Academic Article	Comprehensive kinase profile of pacritinib, a nonmyelosuppressive Janus kinase 2 inhibitor.
Academic Article	Clinical use of ruxolitinib in an academic medical center in unselected patients with myeloproliferative neoplasms not on clinical study.
Academic Article	Complete remission in a patient with JAK2- and IDH2-positive myelofibrosis.
Academic Article	A phase I, open-label, dose-escalation, multicenter study of the JAK2 inhibitor NS-018 in patients with myelofibrosis.
Academic Article	Primary analysis of a phase II open-label trial of INCB039110, a selective JAK1 inhibitor, in patients with myelofibrosis.
Academic Article	Myeloproliferative Neoplasms, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.
Academic Article	A phase 1/2, open-label study evaluating twice-daily administration of momelotinib in myelofibrosis.
Academic Article	Myelofibrosis: an update on drug therapy in 2016.
Academic Article	Phase 1/2 study of pacritinib, a next generation JAK2/FLT3 inhibitor, in myelofibrosis or other myeloid malignancies.
Academic Article	An accurate, simple prognostic model consisting of age, JAK2, CALR, and MPL mutation status for patients with primary myelofibrosis.
Academic Article	A phase 2 study of simtuzumab in patients with primary, post-polycythaemia vera or post-essential thrombocythaemia myelofibrosis.
Academic Article	Haptoglobin is frequently low in patients with myelofibrosis: Clinical relevance.
Academic Article	Investigational Janus kinase inhibitors in development for myelofibrosis.
Academic Article	JAK2 inhibitors for myeloproliferative neoplasms: what is next?
Academic Article	Morphologic and Molecular Characteristics of De Novo AML With JAK2 V617F Mutation.
Academic Article	Ruxolitinib reduces JAK2 p.V617F allele burden in patients with polycythemia vera enrolled in the RESPONSE study.
Academic Article	A phase 2 study of momelotinib, a potent JAK1 and JAK2 inhibitor, in patients with polycythemia vera or essential thrombocythemia.
Academic Article	A phase 1 study of the Janus kinase 2 (JAK2)V617F inhibitor, gandotinib (LY2784544), in patients with primary myelofibrosis, polycythemia vera, and essential thrombocythemia.
Academic Article	JAK2V617F detection and allele burden measurement in saliva vs. peripheral blood in patients with myelofibrosis.
Academic Article	Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis: A Randomized Clinical Trial.
Academic Article	Significance of thrombocytopenia in patients with primary and postessential thrombocythemia/polycythemia vera myelofibrosis.
Academic Article	Sensitive PCR-based monitoring and early detection of relapsed JAK2 V617F myelofibrosis following transplantation.
Academic Article	Precision immunotherapy, mutational landscape, and emerging tools to optimize clinical outcomes in patients with classical myeloproliferative neoplasms.
Academic Article	Phase I study of ruxolitinib in previously treated patients with low or intermediate-1 risk myelodysplastic syndrome with evidence of NF-kB activation.
Academic Article	Myelofibrosis osteoclasts are clonal and functionally impaired.
Academic Article	Unique Case of Myeloproliferative Neoplasm with Two Rare Clonal Abnormalities: Rare JAK2 Exon 12 Mutation and Rare e14a3 (b3a3) BCR/ABL Fusion Transcript.
Academic Article	Utility of JAK2 V617F allelic burden in distinguishing chronic myelomonocytic Leukemia from Primary myelofibrosis with monocytosis.
Academic Article	New Concepts of Treatment for Patients with Myelofibrosis.
Academic Article	Characteristics of patients with myeloproliferative neoplasms with lymphoma, with or without JAK inhibitor therapy.
Academic Article	Janus kinase 2 variants associated with the transformation of myeloproliferative neoplasms into acute myeloid leukemia.
Academic Article	SOHO State of the Art Updates and Next Questions: Myelofibrosis.
Concept	Janus Kinase Inhibitors
Academic Article	Novel Therapies in Myeloproliferative Neoplasms (MPN): Beyond JAK Inhibitors.
Academic Article	Primary myelofibrosis marrow-derived CD14+/CD34- monocytes induce myelofibrosis-like phenotype in immunodeficient mice and give rise to megakaryocytes.
Academic Article	Mutational profiling in myelofibrosis: implications for management.
Academic Article	Concurrent JAK2 V617F and MPL W515L in myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis.
Academic Article	miR-543 regulates the epigenetic landscape of myelofibrosis by targeting TET1 and TET2.
Academic Article	Management of myelofibrosis after ruxolitinib failure.
Academic Article	Givinostat: an emerging treatment for polycythemia vera.
Academic Article	ACVR1/JAK1/JAK2 inhibitor momelotinib reverses transfusion dependency and suppresses hepcidin in myelofibrosis phase 2 trial.
Academic Article	Pacritinib demonstrates spleen volume reduction in patients with myelofibrosis independent of JAK2V617F allele burden.
Academic Article	Diagnostic Performance of Erythropoietin Levels in Polycythemia Vera: Experience at a Comprehensive Cancer Center.
Academic Article	MOMENTUM: momelotinib vs danazol in patients with myelofibrosis previously treated with JAKi who are symptomatic and anemic.
Academic Article	Immunotherapy and Immunomodulation in Myeloproliferative Neoplasms.
Academic Article	Patient-reported Effects of Fedratinib, an Oral, Selective Inhibitor of Janus Kinase 2, on Myelofibrosis-related Symptoms and Health-related Quality of Life in the Randomized, Placebo-controlled, Phase III JAKARTA Trial.
Academic Article	Retrospective analysis of pacritinib in patients with myelofibrosis and severe thrombocytopenia.
Academic Article	SOHO State of the Art Updates and Next Questions: Novel Therapies in Development for Myelofibrosis.
Academic Article	Potential limitations of diagnostic standard codes to distinguish polycythemia vera and secondary erythrocytosis.
Academic Article	Disease Modification in Myelofibrosis: An Elusive Goal?
Academic Article	Mutational landscape of blast phase myeloproliferative neoplasms (MPN-BP) and antecedent MPN.
Academic Article	Managing patients with myelofibrosis and thrombocytopenia.
Academic Article	The clinical dilemma of JAK inhibitor failure in myelofibrosis: Predictive characteristics and outcomes.
Academic Article	Safety and efficacy of fedratinib, a selective oral inhibitor of Janus kinase-2 (JAK2), in patients with myelofibrosis and low pretreatment platelet counts.
Academic Article	Imetelstat in intermediate-2 or high-risk myelofibrosis refractory to JAK inhibitor: IMpactMF phase III study design.
Academic Article	Clinicopathologic spectrum of myeloid neoplasms with concurrent myeloproliferative neoplasm driver mutations and SRSF2 mutations.
Academic Article	Quality of life independently predicts overall survival in myelofibrosis: Key insights from the COntrolled MyeloFibrosis Study with ORal Janus kinase inhibitor Treatment (COMFORT)-I study.
Academic Article	Overall survival in the SIMPLIFY-1 and SIMPLIFY-2 phase 3 trials of momelotinib in patients with myelofibrosis.
Academic Article	Biological drivers of clinical phenotype in myelofibrosis.
Academic Article	Phase III MANIFEST-2: pelabresib?+ ruxolitinib vs placebo?+ ruxolitinib in JAK inhibitor treatment-naive myelofibrosis.
Academic Article	Anemia in myelofibrosis: Current and emerging treatment options.
Academic Article	Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study.
Academic Article	How I manage anemia related to myelofibrosis and its treatment regimens.
Academic Article	Triple-Negative Primary Myelofibrosis: A Bone Marrow Pathology Group Study.
Academic Article	SOHO State of the Art Updates and Next Questions: Novel Therapeutic Strategies in Development for Myelofibrosis.
Academic Article	MANIFEST: Pelabresib in Combination With Ruxolitinib for Janus Kinase Inhibitor Treatment-Na?ve Myelofibrosis.
Academic Article	Cytopenic myelofibrosis: prevalence, relevance, and treatment.
Academic Article	Momelotinib long-term safety and survival in myelofibrosis: integrated analysis of phase 3 randomized controlled trials.
Academic Article	Ten years after ruxolitinib approval for myelofibrosis: a review of clinical efficacy.
Academic Article	Symptomatic benefit of momelotinib in patients with myelofibrosis: Results from the SIMPLIFY phase III studies.
Academic Article	The role of therapy in the outcome of patients with myelofibrosis.
Academic Article	Clinical outcomes of patients with myelofibrosis after immediate transition to momelotinib from ruxolitinib.
Academic Article	Ten years of treatment with ruxolitinib for myelofibrosis: a review of safety.
Academic Article	Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis previously treated with a JAK inhibitor (MOMENTUM): an updated analysis of an international, double-blind, randomised phase 3 study.
Academic Article	Pacritinib is a potent ACVR1 inhibitor with significant anemia benefit in patients with myelofibrosis.

Search Criteria

Janus Kinase 2